2023-06-30 09:59:22 ET
- Telo Genomics ( OTCQB:TDSGF ) has entered into an agreement with Leede Jones Gable to compensate Leede for strategic advice provided in connection with the Company's recently closed $0.25 non-brokered private placement.
- Under the agreement, the Co. will issue to Leede 150K common shares in the capital, and grant 75K common share purchase warrants of the Co.
- Each Warrant will be non-transferable and exercisable to acquire one common share of the Co. at a price of $0.40/common share for a period of 12 months from the date of issuance.
For further details see:
Telo Genomics announces agreement for strategic advisory services